Uncertain price

Free PSa 100test Read more

Free PSa: 100test

100% original

Guarantee of the originality of the product

Payment methods

You can pay for the product in the usual ways

10 days money back guarantee

If you are not satisfied with the product, you can receive your money within ten days after purchase

Introduction Free PSa 100test

Free PSa 100test

Application of Free PSa 100test kit

The PV-FPSA product is based on quantitative immunoassay and based on paramagnetic particles, which is designed for the quantitative measurement of free prostate-specific antigen (FPSA) in human serum and plasma using the PadinAnalyzer immunoassay analyzer.

Basically, PV-FPSA is used to monitor the tumor and its treatment stages. This product should not be used for primary diagnosis and tumor screening.

Prostate-specific antigen or PSA is a glycoprotein serine protease whose proteolytic property is deactivated in complex with protease inhibitors such as 1-antichymotrypsin (ACT), alpha-2-macroglobulin and other acute phase proteins in the blood.

In addition to forming a complex with other agents, this antigen is also present in the blood in a free form, which is inactive in terms of proteolytic properties.

In general, an increase in the concentration of PSA in the serum indicates the pathological state of the prostate (prostatitis, benign hyperplasia or carcinoma). Early diagnosis of prostate carcinoma is a challenge due to the lack of symptoms in affected men, and early diagnosis in people without symptoms with a simple, safe and cheap test is very important.

PSA testing in asymptomatic patients can be of significant value in diagnosing metastatic type or stable disease after surgery and treatment of prostate cancer. Persistent rise in PSA

After treatment, it indicates the recurrent or stable form of the disease. The PSA test is used as an adjunctive test in the management of patients with prostate cancer.

Because PSA antigen is not specific for prostate cancer, PSA tests lack sufficient sensitivity and specificity for early diagnosis and screening of this disease. A number of studies have shown that the percentage of free PSA (FPSA) in patients with prostate cancer is significantly lower than those with benign disease or healthy individuals.

The TPSA/FPSA ratio is used to improve sensitivity and specificity in patients with TPSA values in the "gray zone" (4-10 ng/mL).